Document:

EX-4.2

 Exhibit 4.2 

AUSPEX PHARMACEUTICALS, INC. 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

December 20, 2013 

 AUSPEX PHARMACEUTICALS, INC. 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

This Amended and Restated Investors’ Rights Agreement (the “Agreement”) is made as of December 20, 2013, by and
among Auspex Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the holders of the Company’s Series A-1, Series A-2, Series A-3, Series A-4 and Series A-5 Preferred Stock set forth on Exhibit A attached
hereto (the “Series A Holders”), the holders of Series B Preferred Stock set forth on Exhibit A attached hereto (the “Series B Holders”), the holders of Series C Preferred Stock set forth on Exhibit A
attached hereto (the “Series C Holders”), the holders of Series D Preferred Stock set forth on Exhibit A attached hereto (the “Series D Holders”) and the holders of Series E Preferred Stock set forth on
Exhibit A attached hereto (the “Series E Holders,” and together with the Series A Holders, the Series B Holders, the Series C Holders and the Series D Holders, the “Investors”). 

RECITALS 
 The
Company, the Series A Holders, the Series B Holders, the Series C Holders and the Series D Holders are parties to that certain Amended and Restated Investors’ Rights Agreement dated October 31, 2012, as amended (the “Prior
Agreement”). The Company and the Series E Holders are parties to that certain Series E Preferred Stock Purchase Agreement of even date herewith (the “Purchase Agreement”). In order to induce the Series E Holders to
purchase Series E Preferred Stock and invest funds in the Company pursuant to the Purchase Agreement, the Company, the Series A Holders, the Series B Holders, the Series C Holders and the Series D Holders hereby agree that the Prior Agreement is
superseded and replaced in its entirety with this Agreement, and that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common Stock issued or issuable to them and certain other matters as set forth
herein. 
 AGREEMENT 

The parties hereby agree as follows: 

1. Registration Rights. The Company and the Investors covenant and agree as follows: 

1.1 Definitions. For purposes of this Section 1: 

(a) “Affiliated Funds” shall have the meaning ascribed to such term in the Charter; 

(b) “Board” means the Company’s Board of Directors; 

 (c) “Charter” means the Company’s Amended and Restated Certificate of
Incorporation, as such may be amended and/or restated from time to time; 
 (d) “Common Stock” means the Company’s
Common Stock, par value $0.0001 per share; 
 (e) “Exchange Act” means the Securities Exchange Act of 1934, as amended
(and any successor thereto) and the rules and regulations promulgated thereunder; 
 (f) “Excluded Registration” means
(i) a registration statement relating solely to the sale of securities to employee, consultant and director participants in a stock plan of the Company, (ii) a registration relating to a corporate reorganization or other transaction under
Rule 145 of the Securities Act, (iii) a registration relating solely to the offer and sale of debt securities, or (iv) a registration on any registration form that does not permit secondary sales; 

(g) “Form S-3” means such form under the Securities Act as in effect on the
date hereof or any successor form under the Securities Act that permits significant incorporation by reference of the Company’s subsequent public filings under the Exchange Act; 

(h) “Holder” means any Investor owning or having the right to acquire Registrable Securities or any assignee thereof in
accordance with Section 1.12 of this Agreement; 
 (i) “Major Investor” means any Investor that holds at least
5,000,000 shares of the Preferred Stock or the Common Stock issued upon conversion thereof (subject to adjustment for stock splits, stock dividends, combinations, reclassifications or the like). A Major Investor includes any general partners,
managing members and affiliates of a Major Investor, including Affiliated Funds; 
 (j) “Qualified IPO” means a firm
commitment underwritten public offering by the Company of shares of its Common Stock prior to or in connection with which all the then-outstanding shares of Preferred Stock are converted into shares of Common Stock pursuant to the Charter; 

(k) “Register,” “registered,” and “registration” refer to a registration effected by
preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document; 

(l) “Registrable Securities” means (i) the shares of Common Stock issuable or issued upon conversion of the Series A-1
Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series A-5 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock (together, the
“Preferred Stock”) held by the Holders and any assignee thereof in accordance with Section 1.12 of this Agreement, and (ii) any other shares of Common Stock issued as (or issuable

  
 -2- 

 
upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares
listed in (i); excluding, however, in all cases any Registrable Securities sold in a transaction in which the rights under this Agreement are not assigned, or any shares for which registration rights have terminated pursuant to
Section 1.15 of this Agreement; 
 (m) The number of shares of “Registrable Securities then outstanding” shall be
determined by the number of shares of Common Stock outstanding which are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities which are, Registrable Securities; 

(n) “SEC” means the Securities and Exchange Commission; and 

(o) “Securities Act” means the Securities Act of 1933, as amended (and any successor thereto) and the rules and regulations
promulgated thereunder. 
 1.2 Request for Registration. 

(a) If the Company shall receive at any time after the earlier of (i) December 20, 2016, or (ii) six months after the effective date
of the Qualified IPO, a written request from the Holders of a majority of the Registrable Securities then outstanding (the “Initiating Holders”) that the Company file a registration statement under the Securities Act covering the
registration of Registrable Securities with an anticipated aggregate offering price of at least $5,000,000, then the Company shall, within 20 days after receiving such request, give written notice of such request to all Holders and shall, subject to
the limitations of subsection 1.2(b), use commercially reasonable efforts to cause to be registered under the Securities Act all of the Registrable Securities that each such Holder has requested to be registered within 20 days after the mailing
of such notice by the Company. 
 (b) If the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request and the Company shall include such information in the written notice referred to in subsection 1.2(a). The underwriter will be selected by the Company, which
underwriter shall be reasonably acceptable to a majority in interest of the Holders whose Registrable Securities are to be included in the underwriting. In such event, the right of any Holder to include his Registrable Securities in such
registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the
Initiating Holders and such Holder) to the extent provided herein. The Company and all Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or
underwriters selected for such underwriting. Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Company in good faith that marketing factors require a limitation of the number of shares to

  
 -3- 

 
be underwritten, then the Company shall so advise all Holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities
that may be included in the underwriting shall be allocated among all participating Holders thereof, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned by each
participating Holder. In no event shall any Registrable Securities be excluded from such underwriting unless all other securities are first excluded from such offering. Any Registrable Securities excluded from or withdrawn from such underwriting
shall be withdrawn from registration. 
 (c) Notwithstanding the foregoing, if the Company shall furnish to the Initiating Holders a
certificate signed by the President of the Company stating that in the good faith judgment of the Board it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed, the Company shall have the
right to defer such filing for a period of not more than 90 days after receipt of the request of the Initiating Holders; provided, however, that the Company may not utilize this right or the similar right set forth in
Section 1.4(b)(iii) more than once in any 12-month period, and provided, further, that the Company shall not register any securities for the account of itself or any other stockholder during such 90-day period (other than in a
Qualified IPO or an Excluded Registration). 
 (d) In addition, the Company shall not be obligated to effect, or to take any action to
effect, any registration pursuant to this Section 1.2: 
 (i) After the Company has effected two registrations pursuant to this
Section 1.2 provided, however, that such registrations have been declared or ordered effective and that either (A) the conditions of Section 1.5(a) have been satisfied or (B) the registration statements remain
effective and there are no stop orders in effect to such registration statements; 
 (ii) During the period starting with the date 90 days
prior to the Company’s good faith estimate of the date of filing of, and ending on a date 180 days after the effective date of, a registration subject to Section 1.3 hereof unless such offering is not the initial public offering of the
Company’s securities, in which case, ending on a date 90 days after the effective date of such registration subject to Section 1.3 hereof; provided that the Company is actively employing in good faith commercially reasonable efforts to
cause such registration statement to become effective; or 
 (iii) If the Initiating Holders propose to dispose of shares of Registrable
Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.4 below. 
 1.3
Company Registration. 
 (a) If (but without any obligation to do so) the Company proposes to register (including for
this purpose a registration effected by the Company for stockholders other 

  
 -4- 

 
than the Holders) any of its stock under the Securities Act in connection with the public offering of such securities solely for cash (other than an Excluded Registration), the Company shall, at
such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within 20 days after mailing of such notice by the Company in accordance with Section 3.5, the Company shall, subject to the
provisions of Section 1.8, use commercially reasonable efforts to cause to be registered under the Securities Act all of the Registrable Securities that each such Holder has requested to be registered if any stock of the Company is registered.

 (b) The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 1.3 prior to the
effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The expenses of such registration shall be borne by the Company, in accordance with Section 1.7 hereof. 

1.4 Form S-3 Registration. In case the Company shall receive from any Holder or Holders
of the Registrable Securities then outstanding a written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of
the Registrable Securities owned by such Holder or Holders, the Company will: 
 (a) promptly give written notice of the proposed
registration, and any related qualification or compliance, to all other Holders; and 
 (b) use commercially reasonable efforts to effect,
as soon as practicable, such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable
Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within 15 days after receipt of such
written notice from the Company; provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.4: (i) if
Form S-3 is not available for such offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose
to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than $1,000,000; (iii) if the Company shall furnish to the Holders a certificate signed by the President of the Company stating that
in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed, the Company shall have the right to defer such filing for a period of not more than 90 days
after receipt of the request of the Holder or Holders under this Section 1.4; provided, however, that the Company shall not utilize this right or the similar right set forth in Section 1.2(c) more than once in any 12-month
period, and provided, further, that the Company shall not register any securities for the account of itself or any other stockholder during such 90-day period (other than an Excluded Registration); (iv) in any jurisdiction in
which the Company would be required to 

  
 -5- 

 
qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance unless the Company is already qualified to do business or
subject to service of process in that jurisdiction; or (v) during the period ending 180 days after the effective date of a registration statement subject to Section 1.3. 

(c) Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so
requested to be registered as soon as practicable after receipt of the request or requests of the Holders. Registrations effected pursuant to this Section 1.4 shall not be counted as demands for registration or registrations effected pursuant
to Sections 1.2 or 1.3, respectively. 
 1.5 Obligations of the Company. Whenever required under this
Section 1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a)
Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use commercially reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority
of the Registrable Securities registered thereunder, keep such registration statement effective for up to 120 days, or until the distribution described in such registration statement is completed, if earlier. 

(b) Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with
such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for up to 120 days, or until the distribution described in
such registration statement is completed, if earlier. 
 (c) Promptly notify the Holders of the effectiveness of such registration
statement, and furnish to the Holders such numbers of copies of a prospectus, including any supplement to the prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to
facilitate the disposition of Registrable Securities owned by them. 
 (d) Following the effective date of such registration statement,
notify the Holders of any request by the SEC that the Company amend or supplement such registration statement, or the associated prospectus. 

(e) Use commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions unless the Company is already qualified to do business or subject to service of process in that jurisdiction. 

  
 -6- 

 (f) In the event of any underwritten public offering, enter into and perform its obligations
under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder and other security holder participating in such underwriting shall also enter into and perform its obligations under such an
agreement. 
 (g) Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus
relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or
omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing, such obligation to continue for 120 days or until the distribution described in
such registration statement is completed, if earlier. 
 (h) Cause all such Registrable Securities registered pursuant to this
Section 1 to be listed on each national securities exchange or trading system on which similar securities issued by the Company are then listed. 

(i) Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereunder and a CUSIP number for all such
Registrable Securities, in each case not later than the effective date of such registration. 
 (j) Make generally available to its
security holders, and to deliver to each Holder participating in the registration statement, an earnings statement of the Company that will satisfy the provisions of Section 11(a) of the Securities Act covering a period of 12 months beginning
after the effective date of such registration statement as soon as reasonably practicable after the termination of such 12-month period. 

1.6 Information From Holders. It shall be a condition precedent to the obligations of the Company to take any action pursuant to
this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding such Holder, the Registrable Securities held by it, and the intended method of disposition
of such securities as shall be required to effect the registration of such Holder’s Registrable Securities. The Company shall have no obligation with respect to any registration requested pursuant to Section 1.2 or Section 1.4 of this
Agreement if, as a result of the application of the preceding sentence, the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the anticipated aggregate offering price
required to originally trigger the Company’s obligation to initiate such registration as specified in subsection 1.2(a) or subsection 1.4(b)(2), whichever is applicable. 

1.7 Expenses of Registration. All expenses other than underwriting discounts and commissions incurred in connection with
registrations, filings or qualifications pursuant to Sections 1.2, 1.3 and 1.4 including (without limitation) all registration, filing and 

  
 -7- 

 
qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company, and the reasonable fees and disbursements of one counsel for the selling Holders
selected by them with the approval of the Company, which approval shall not be unreasonably withheld, shall be borne by the Company. 
 1.8
Underwriting Requirements. In connection with any offering involving an underwriting of shares of the Company’s capital stock, the Company shall not be required under Section 1.3 to include any of the Holders’ securities
in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters selected by the Company (or by other persons entitled to select the underwriters), and then only in such quantity as the
underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds
the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such
securities, including Registrable Securities, which the underwriters determine in their sole discretion will not jeopardize the success of the offering (the securities so included to be apportioned pro rata among the selling stockholders according
to the total amount of securities entitled to be included therein owned by each selling stockholder or in such other proportions as shall mutually be agreed to by such selling stockholders) but in no event shall the amount of securities of the
selling Holders included in the offering be reduced below 30% of the total amount of securities included in such offering, unless such offering is the initial public offering of the Company’s securities, in which case, the selling stockholders
may be excluded if the underwriters make the determination described above and no other stockholder’s securities are included. For purposes of the preceding parenthetical concerning apportionment, for any selling stockholder which is a holder
of Registrable Securities and which is a venture capital fund, or a partnership or corporation, the Affiliated Funds, partners, retired partners and stockholders of such holder, or the estates and family members of any such partners and retired
partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling stockholder,” and any pro-rata reduction with respect to such “selling stockholder” shall be based upon the
aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “selling stockholder,” as defined in this sentence. 

1.9 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

1.10 Indemnification. In the event any Registrable Securities are included in a registration statement under this
Section 1: 

  
 -8- 

 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder,
any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities
(joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any
of the following statements, omissions or violations (collectively a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary
prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not
misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities
law; and the Company will pay to each such Holder, underwriter or controlling person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or
action; provided, however, that the indemnity agreement contained in this subsection 1.10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected
without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable to any Holder, underwriter or controlling person for any such loss, claim, damage, liability, or action to the extent that it
arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by any such Holder, underwriter or controlling person. 

(b) To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its
officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter, any other Holder selling securities in such registration statement and any controlling
person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Securities Act, the Exchange Act or other federal or state
law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in
conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person intended to be indemnified
pursuant to this subsection 1.10(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this subsection 1.10(b) shall
not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided, that in no event shall
any indemnity under this 

  
 -9- 

 
subsection 1.10(b) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 1.10 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.10, deliver to the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the
parties; provided, however, that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the reasonable fees
and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and
any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action,
shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.10, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any
indemnified party otherwise than under this Section 1.10. 
 (d) If the indemnification provided for in this Section 1.10 is held
by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder,
shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and
of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations; provided, that in no event shall any
contribution by a Holder under this Subsection 1.10(d) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. The relative fault of the indemnifying party and of the indemnified party
shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by
the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

  
 -10- 

 (f) The obligations of the Company and Holders under this Section 1.10 shall survive the
completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise. 
 1.11
Reports Under the Exchange Act. With a view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell
securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to: 

(a) make and keep public information available, as those terms are understood and defined in SEC Rule 144, at all times after 90 days
after the effective date of the Qualified IPO so long as the Company remains subject to the periodic reporting requirements under Sections 13 or 15(d) of the Exchange Act; 

(b) take such action, including the voluntary registration of its Common Stock under Section 12 of the Exchange Act, as is necessary to
enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first registration
statement filed by the Company for the offering of its securities to the general public is declared effective; 
 (c) file with the SEC in
a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and 
 (d) furnish
to any Holder upon request, so long as the Holder owns any Registrable Securities, (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after 90 days after the effective
date of the Qualified IPO), the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such
other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 

1.12 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this
Section 1 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee (i) of at least 50,000 shares of such securities (subject to adjustment for stock splits, stock dividends, reclassification or the
like) (or if the transferring Holder owns less than 50,000 shares of such securities, then all Registrable Securities held by the transferring Holder), (ii) that is a subsidiary, parent, partner, limited partner, retired partner, member,
retired member or stockholder of a Holder, (iii) that is an Affiliated Fund, (iv) who is a Holder’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law,
daughter-in-law, brother-

  
 -11- 

 
in-law, or sister-in-law (such a relation, a Holder’s “Immediate Family Member”, which term shall include adoptive relationships), or (v) that is a trust for the
benefit of an individual Holder or such Holder’s Immediate Family Member, provided the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the
securities with respect to which such registration rights are being assigned; and provided, further, that such assignment shall be effective only if the transferee agrees in writing to be bound by this Agreement and immediately
following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Securities Act. For the purposes of determining the number of shares of Registrable Securities held by a transferee or assignee,
the holdings of transferees and assignees of (x) a partnership who are partners or retired partners of such partnership or (y) a limited liability company who are members or retired members of such limited liability company (including
Immediate Family Members of such partners or members who acquire Registrable Securities by gift, will or intestate succession) shall be aggregated together and with the partnership or limited liability company; provided that all assignees and
transferees who would not qualify individually for assignment of registration rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices or taking any action under Section 1. 

1.13 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without
the prior written consent of the Holders of a majority of the outstanding Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company which would allow such holder or prospective holder
(a) to include any of such securities in any registration filed under Sections 1.2, 1.3 or 1.4 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to
the extent that the inclusion of his securities will not reduce the amount of the Registrable Securities of the Holders which is included or (b) to make a demand registration which could result in such registration statement being declared
effective prior to the earlier of either of the dates set forth in subsection 1.2(a) or within 120 days of the effective date of any registration effected pursuant to Section 1.2. 

1.14 Lock-Up Agreement. 

(a) Lock-Up Period; Agreement. In connection with the initial public offering of the Company’s securities and upon request
of the Company or the underwriters managing such offering of the Company’s securities, each Holder agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company
held immediately prior to the closing of the initial public offering, however or whenever acquired (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such
period of time (not to exceed 180 days but subject to such extension or extensions as may be required by the underwriters in order to publish research reports while complying with the Rule 2711 of FINRA) from the effective date of such registration
statement as may be requested by the Company or 

  
 -12- 

 
such managing underwriters and to execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the Company’s initial public offering; provided,
however, that any such restrictions shall not apply to any securities of the Company purchased by Deerfield Management Company, L.P. (“Deerfield”) or its affiliated entities in the initial public offering or in open-market
transactions of freely tradable securities following the initial public offering. 
 (b) Limitations. The obligations
described in Section 1.14(a) shall apply only if all officers and directors of the Company and all greater than 1% stockholders enter into similar agreements, and shall not apply to a registration relating solely to employee benefit plans, or
to a registration relating solely to a transaction pursuant to Rule 145 under the Securities Act. 
 (c) Stop-Transfer
Instructions. In order to enforce the foregoing covenants, the Company may impose stop-transfer instructions with respect to the securities of each Holder (and the securities of every other person subject to the restrictions in Section
1.14(a)). 
 (d) Transferees Bound. Each Holder agrees that prior to the Company’s initial public offering it will not
transfer securities of the Company unless each transferee agrees in writing to be bound by all of the provisions of this Section 1.14, provided that this Section 1.14(d) shall not apply to transfers pursuant to a registration
statement or transfers after the 12-month anniversary of the effective date of the Company’s initial public offering subject to this Section 1.14. 

(e) Legend. Each Holder agrees that a legend reading substantially as follows shall be placed on all certificates representing
all Registrable Securities of each Holder (and the shares or securities of every other person subject to the restriction contained in this Section 1.14): 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD OF UP TO 180 DAYS AFTER THE EFFECTIVE DATE OF THE
ISSUER’S REGISTRATION STATEMENT FILED UNDER THE ACT, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER’S PRINCIPAL OFFICE. SUCH LOCK-UP
PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES.” 
 1.15 Termination of Registration Rights. No Holder shall be
entitled to exercise any right provided for in this Section 1 with respect to any Holder at such time after the 

  
 -13- 

 
Qualified IPO as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without registration within any three-month
period. 
 2. Covenants of the Company. 

2.1 Matters Requiring Director Approval. In addition to any other vote or consent required herein or by law, the affirmative
prior approval of a majority of the Board shall be necessary to approve the following actions: 
 (a) making any loan or advance to any
person, including any employee, officer or director of the Company, except for advances and similar expenditures made in the ordinary course of business; 

(b) altering or amending the terms of the Company’s 2010 Equity Incentive Plan (the “Option Plan”); 

(c) guaranteeing any indebtedness, except for trade accounts of the Company or any subsidiary of the Company arising in the ordinary course
of business; 
 (d) making any investment other than investments in prime commercial paper, money market funds or investments of similar
risk profile; 
 (e) incurring any indebtedness in excess of $100,000 that is not included in a budget approved by the Board, except for
trade credit incurred in the ordinary course of business; 
 (f) entering into any transaction with any director, officer or employee of
the Company, or any entity or person that is affiliated or economically associated with the Company, or any director, officer or employee of the Company; 

(g) hiring, terminating, or altering the compensation of any executive officer of the Company, or approving any option plan or option grant
for any executive officer of the Company; 
 (h) changing the principal place of business of the Company, entering into a new line of
business, or exiting the current line of business of the Company; 
 (i) selling, transferring, entering into an exclusive license
agreement for, pledging or encumbering technology or intellectual property of the Company, other than licenses granted in the ordinary course of business; 

(j) entering into any joint venture, strategic transaction, acquisition or material investment; or 

(k) authorizing a budget or operating plan for any fiscal year. 

  
 -14- 

 2.2 Delivery of Financial Statements. The Company shall deliver to each Major
Investor: 
 (a) as soon as practicable, but in any event within 180 days after the end of each fiscal year of the Company, an income
statement for such fiscal year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such year, and a statement of cash flows for such year, such year-end financial reports to be in reasonable detail, prepared
in accordance with generally accepted accounting principles (“GAAP”), and audited and certified by an independent public accounting firm of nationally recognized standing selected by the Company; 

(b) as soon as practicable, but in any event within 30 days after the end of each of the first three quarters of each fiscal year of the
Company, an unaudited profit or loss statement, a statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter; 

(c) within 30 days of the end of each month, an unaudited income statement and a statement of cash flows and balance sheet for and as of the
end of such month, in reasonable detail; 
 (d) as soon as practicable, but in any event at least 10 days prior to the end of each fiscal
year, an operating budget forecasting the Company’s revenues, expenses and cash position, together with a business plan for the next fiscal year, each prepared on a monthly basis and approved by the Board no later than 30 days following the
beginning of such fiscal year, and, as soon as prepared, any other updated or revised budgets for such fiscal year, prepared by the Company and approved by the Board; 

(e) as soon as practicable after the end of each fiscal year of the Company, a capitalization table of the Company as of a current date,
certified by the Chief Financial Officer of the Company; 
 (f) with respect to the financial statements called for in subsections (b)
and (c) of this Section 2.2, an instrument executed by the Chief Financial Officer or President of the Company and certifying on behalf of the Company that such financials were prepared in accordance with GAAP consistently applied with
prior practice for earlier periods (with the exception of footnotes that may be required by GAAP) and fairly present the financial condition of the Company and its results of operation for the period specified, subject to year-end audit adjustment,
provided that the foregoing shall not restrict the right of the Company to change its accounting principles consistent with GAAP, if the Board or a committee thereof determines that it is in the best interest of the Company to do so; and 

(g) as soon as practicable, such other information relating to the financial condition, business, prospects or corporate affairs of the
Company as may be reasonably requested by a Major Investor. 

  
 -15- 

 2.3 Inspection. The Company shall permit each Major Investor, at such Major
Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be
requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 2.3 to provide access to any information which it reasonably considers to be a trade secret or similar
confidential proprietary information (unless covered by an enforceable confidentiality agreement, in form satisfactory to the Company). 

2.4 Board Observer Rights. The Company shall allow one representative designated by Panorama Capital, L.P. or its Affiliated
Funds (“Panorama”) and one representative designated by Deerfield to attend all meetings of the Board in a nonvoting capacity, and in connection therewith, the Company shall give such representatives copies of all notices, minutes,
consents and other materials, financial or otherwise, which the Company provides to its Board at the same time and in the same manner as provided to its Board; provided, however, that the Company reserves the right to exclude such
representatives from access to any material or meeting or portion thereof if the Board determines in good faith, upon advice of counsel, that such exclusion is reasonably necessary to preserve the attorney-client privilege or to protect highly
confidential information. The decision of the Board with respect to the privileged or highly confidential nature of such information shall be final and binding. 

2.5 Right of First Offer. Subject to the terms and conditions specified in this Section 2.5, the Company hereby grants to
each Major Investor a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). For purposes of this Section 2.5, Major Investor includes any general partners, managing members and affiliates of a
Major Investor, including Affiliated Funds. A Major Investor who chooses to exercise the right of first offer may designate as purchasers under such right itself or its partners or affiliates, including Affiliated Funds, in such proportions as it
deems appropriate. 
 Each time the Company proposes to offer any shares of, or securities convertible into or exercisable for any shares
of, any class of its capital stock (“Shares”), the Company shall first make an offering of such Shares to each Major Investor in accordance with the following provisions: 

(a) The Company shall deliver a notice (the “RFO Notice”) to the Major Investors stating (i) its bona fide intention to
offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Shares. 

(b) Within 30 days after delivery of the RFO Notice, the Major Investor may elect to purchase or obtain, at the price and on the terms
specified in the RFO Notice, up to that portion of such Shares which equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion and exercise of all convertible

  
 -16- 

 
or exercisable securities then held, by such Major Investor bears to the total number of shares of Common Stock then outstanding (assuming conversion of all outstanding shares of Preferred
Stock). Such purchase shall be completed at the same closing as that of any third party purchasers or at an additional closing. The Company shall promptly, in writing, inform each Major Investor that elects to purchase all the shares available to it
(each, a “Fully-Exercising Investor”) of any other Major Investor’s failure to do likewise. During the 10-day period commencing after receipt of such information, each Fully-Exercising Investor shall be entitled to obtain that portion of the Shares for which Major Investors were entitled to subscribe but which were not subscribed for by the Major Investors that is equal to the
proportion that the number of shares of Common Stock issued and held, or issuable upon conversion and exercise of all convertible or exercisable securities then held, by such Fully-Exercising Investor bears to the total number of shares of Common
Stock then outstanding (assuming conversion of all outstanding shares of Preferred Stock) and held by all Fully-Exercising Investors who wish to purchase the unsubscribed Shares. 

(c) The Company may, during the 45-day period following the expiration of the period provided in
subsection 2.5(b) hereof, offer the remaining unsubscribed portion of the Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than those specified in the RFO Notice. If the Company does not
enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within 60 days after the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be
offered unless first reoffered to the Major Investors in accordance herewith. 
 (d) The right of first offer in this Section 2.5
shall not be applicable to the issuance of Exempted Securities (as defined in the Charter). In addition to the foregoing, the right of first offer in this Section 2.5 shall not be applicable with respect to any Major Investor and any subsequent
securities issuance, if (i) at the time of such subsequent securities issuance, the Major Investor is not an “accredited investor,” as that term is then defined in Rule 501(a) under the Securities Act, and (ii) such subsequent
securities issuance is otherwise being offered only to accredited investors. 
 2.6 Qualified Small Business Stock Status. In
the event that the Company proposes to take an action or engage in a transaction that would reasonably be expected to result in the Shares no longer being “qualified small business stock” within the meaning of Section 1202(c) of the
Internal Revenue Code of 1986, as amended (the “Code”), the Company shall notify the Investors and consult in good faith to devise a mutually agreeable and reasonable alternative course of action or transaction structure that would
preserve such status. In addition, the Company shall submit to the Investors and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Code and any related Treasury Regulations. In addition, within
ten (10) days after any Investor has delivered to the Company a written request therefor, the Company shall deliver to such Investor a written statement informing the Investor whether, in the Company’s good-faith judgment after a
reasonable investigation, such 

  
 -17- 

 
Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code, or would constitute “qualified small business
stock,” if determination of whether stock constitutes “qualified small business stock” were made by taking into account the modifications set forth in Section 1045(b)(4) of the Code. The Company’s obligation to furnish a
written statement pursuant to this Section 2.6 shall continue notwithstanding the fact that a class of the Company’s stock may be traded on an established securities market. 

2.7 Employee Matters. 

(a) Shares or options issued or issuable by the Company to officers, directors, employees and consultants of the Company pursuant to the
Option Plan (or any stock plan adopted in the future) (i) shall be subject to four-year vesting, with a one-year cliff for 25% of the shares and monthly vesting thereafter, provided that this formula may be modified by a majority of the Board
for specific grants to individuals and performance-based awards that, if made, may vest upon satisfactory completion of the performance goals and (ii) will not provide for acceleration triggered only by a Liquidation Transaction (as defined in
the Charter), provided that the Board shall not be restricted in its ability to accelerate the vesting of awards under the Option Plan at the time of a Liquidation Transaction so long as the Series D Representative (as defined in the Charter), if
any, concurs in such decision to accelerate vesting. Granting of all awards under the Option Plan will be subject to approval by the Compensation Committee of the Board and approval or ratification by the Board. 

(b) Unless otherwise determined by the Board, the Company shall require all future officers, directors, and employees of, and consultants to,
the Company to execute and deliver a Confidential Information and Invention Assignment Agreement in such form as has been or may be approved by the Board from time to time, including the Series C Preferred Stock and Series D Preferred Stock director
representatives then in office. 
 2.8 Board Committees. Each Committee of the Board shall include at least one member
designated by Panorama or its Affiliated Funds, Thomas, McNerney & Partners, L.P. or its Affiliated Funds, CMEA Ventures VI, L.P. (“CMEA”) or its Affiliated Funds, or Sloan Biotech or its Affiliated Funds. 

2.9 Compensation Committee. The Compensation Committee of the Board shall include the member designated by Thomas,
McNerney & Partners, L.P. or its Affiliated Funds, who shall serve as Chairman, and the member designated by Panorama or its Affiliated Funds. The Compensation Committee will recommend, and the Board will approve, any compensation or equity
issuance to employees or consultants to the Company, or the amendment of any existing employment or consulting agreement or arrangement as of the date hereof. 

2.10 Director and Officer Liability. 

(a) The Company shall maintain in full force and effect director and officer liability insurance in an amount to be determined by the Board.
The Charter and the Company’s Bylaws will provide (a) for elimination of the liability of each member of the Board 

  
 -18- 

 
to the maximum extent permitted by law and (b) for indemnification of each member of the Board for acts on behalf of the Company to the maximum extent permitted by law. In addition, the
Company will enter into and use its best efforts to at all times maintain reasonable and customary indemnification agreements with each member of the Board to indemnify such directors to the maximum extent permissible under applicable law. 

(b) If the Company or any of its successors or assignees consolidates with or merges into any other person and is not the continuing or
surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification
of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, the Charter, indemnification agreements, or elsewhere, as the case may be. 

2.11 Termination of Covenants. 

(a) The covenants set forth in Sections 2.1 through Section 2.10(a) shall terminate as to each Holder and be of no further force or
effect (i) immediately prior to the consummation of a Qualified IPO, or (ii) upon termination of the Agreement, as provided in Section 3.1. 

(b) The covenants set forth in Sections 2.2 and 2.3 shall terminate as to each Holder and be of no further force or effect when the
Company first becomes subject to the periodic reporting requirements of Sections 13 or 15(d) of the Exchange Act, if this occurs earlier than the events described in Section 2.11(a) above. 

3. Miscellaneous. 

3.1 Termination. This Agreement shall terminate, and have no further force and effect, when the Company shall consummate a
Liquidation Transaction; provided, however, that the provisions of Section 2.10(b) shall survive such termination. 
 3.2
Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto pertaining to the subject matter hereof, and any and all other written or oral agreements relating to the subject matter hereof existing
between the parties hereto are expressly canceled. This Agreement supersedes and replaces in its entirety the Prior Agreement in its entirety, and such Prior Agreement shall be of no further force or effect upon execution of this Agreement by all
parties hereto. 
 3.3 Successors and Assigns. Except as otherwise provided in this Agreement, the terms and conditions of
this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any of the Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock,
Series A-4 Preferred Stock, Series A-5 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock, or any Common Stock issued upon 

  
 -19- 

 
conversion thereof). For the avoidance of doubt, the Company and each Investor agree that CMEA may, without the consent of the Company or any other person, transfer the rights granted to it
hereunder to any other investment vehicle managed by an affiliate of CMEA to whom it transfers all or any of the shares of the Preferred Stock or the Common Stock issued upon conversion thereof, and such investment vehicle shall be deemed an
“Affiliated Fund” as defined in Section 1.1(a) hereof. For the avoidance of doubt, the Company and each Investor agree that any other Investor may, without the consent of the Company or any other person, transfer the rights granted to
such Investor hereunder to any Affiliated Funds to which such Investor transfers any or all of the shares of Preferred Stock or the Common Stock issued upon conversion thereof held by such Investor. Nothing in this Agreement, express or implied, is
intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

3.4 Amendments and Waivers. Any term of this Agreement may be amended, waived or terminated only with the written consent of the
Company and the holders of a majority of the Registrable Securities then outstanding; provided, however, that (i) any amendment that adversely affects the rights granted the Holders of a particular series of Preferred Stock
hereunder in a manner different from the Holders of any other series of Preferred Stock must be approved by the holders of a majority of such series of Preferred Stock then outstanding, except with respect to the Series D Preferred Stock, which must
be approved by the holders of at least 75% of the Series D Preferred Stock, (ii) any amendment or waiver of the rights granted to the Major Investors in this Agreement shall require the consent of a majority in interest of the Registrable
Securities held by the Major Investors, (iii) any amendment or waiver of the rights granted to the Major Investors in Section 2.5 above (whether directly or indirectly by way of amendment to the definition of “Exempted
Securities” as defined in the Charter) shall require the consent of the holders of a majority of Series E Preferred Stock to the extent such amendment or waiver reduces the number of shares that holders of Series E Preferred Stock (in their
capacity as such) may purchase in such transaction; (iv) any amendment to Section 2.4 that restricts or is adverse to the rights of Deerfield thereunder shall require the consent of Deerfield; and (v) any amendment to
Section 1.14 that restricts the right of Deerfield to transfer or sell securities purchased in an initial public offering or in the open market of freely tradable securities thereafter shall require the consent of the holders of a majority of
the Series E Preferred Stock. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless
such amendment, termination or waiver applies to all Investors in the same fashion; provided, however, that any amendment or waiver of the rights granted to the Major Investors in Section 2.5 above that does not require the consent of the holders of
a majority of the Series E Preferred Stock as set forth in sub-clause (iii) of this Section 3.4 shall not require the written consent of any Holder of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock or Series D Preferred
Stock (in their capacity as such) provided that such amendment or waiver impacts holders of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock in the same fashion. Any amendment or waiver
effected in accordance with this paragraph shall be binding upon each party to the Agreement, whether or not such party has signed such amendment or waiver, each future holder 

  
 -20- 

 
of all such Registrable Securities, and the Company. The Company shall give prompt notice of any amendment or termination hereof, or any waiver hereunder, to any party to this Agreement that did
not consent in writing to such amendment, termination or waiver. 
 3.5 Notices. Unless otherwise provided, any notice
required or permitted by this Agreement shall be in writing and shall be deemed sufficient upon delivery, when delivered personally or by overnight courier or sent by facsimile, or 48 hours after being deposited in the U.S. mail, as certified or
registered mail, with postage prepaid, and addressed to the party to be notified at such party’s address or facsimile number as set forth on the signature page hereto or as subsequently modified by written notice, and (a) if to the
Company, with a copy to Frederick T. Muto, Esq., Cooley LLP, 4401 Eastgate Mall, San Diego, California 92121 and (b) if to Panorama, with a copy to Ella DeTrizio, Esq., Dechert LLP, 902 Carnegie Center, Suite 500, Princeton, New
Jersey 08540. 
 3.6 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable
law, such provision shall be excluded from this Agreement, and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

3.7 Governing Law. This Agreement and all acts and transactions pursuant hereto shall be governed, construed and interpreted in
accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of laws. 
 3.8
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

3.9 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 
 3.10 Aggregation of Stock. All shares of the Preferred Stock held
or acquired by affiliated entities or persons, including Affiliated Funds, shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

[Signature Pages Follow] 

  
 -21- 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first above written. 
  

			
	COMPANY:
	
	AUSPEX PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Pratik Shah, Ph.D.

		 	 Pratik Shah, Ph.D.
 President and Chief
Executive Officer

	
	 Address: 3366 N. Torrey Pines Road, Suite 225

                La Jolla, CA 92037

 [SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 INVESTORS: 
  

			
	THOMAS, MCNERNEY & PARTNERS II, L.P.
	
	 By: Thomas, McNerney & Partners II, LLC

Its: General Partner

		
	By:	 	 /s/ Alex Zisson

	Name: Alex Zisson
	Title: Partner
	
	 Address:      3366 N. Torrey Pines Road

                   
 Suite 220

                   
 La Jolla, CA 92037

	
	TMP NOMINEE II, LLC
		
	By:	 	 /s/ Alex Zisson

	Name: Alex Zisson
	Title: Partner
	
	 Address:      3366 N. Torrey Pines Road

                   
 Suite 220

                   
 La Jolla, CA 92037

	
	 TMP ASSOCIATES II, L.P.
  

By: Thomas, McNerney & Partners II, LLC
 Its: General
Partner

		
	By:	 	 /s/ Alex Zisson

	Name: Alex Zisson
	Title: Partner
	
	 Address:      3366 N. Torrey Pines Road

                   
 Suite 220

                   
 La Jolla, CA 92037

 [SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 INVESTORS: 
  

			
	CMEA VENTURES VII, L.P.
		
	By:	 	 /s/ David Collier

	Name: David Collier
	Title: Managing Director
	
	 Address:      One Letterman Drive

                   
 Building C, Suite CM500

                   
 San Francisco, CA 94129

	
	 By: CMEA Ventures VII, GP, LLC
 Its:
General Partners

	
	CMEA VENTURES VII (PARALLEL), L.P.
		
	By:	 	 /s/ David Collier

	Name: David Collier
	Title: Managing Director
	
	 By: CMEA Ventures VII GP, L.P.
 Its:
General Partner
  
 By: CMEA Ventures VII GP, LLC

Its: General Partner

	
	 Address:      One Letterman Drive

                   
 Building C, Suite CM500

 [SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 INVESTORS: 
  

			
	COSTA VERDE CAPITAL LLC
		
	By:	 	 /s/ Sepehr Sarshar

	Name: Sepehr Sarshar
	Its: Manager
	
	 Address:      2460 Oxford Avenue

                   
 Cardiff CA 92007

                   
 Attention: Sep Sarshar

	
	COSTA VERDE CAPITAL II LLC
		
	By:	 	 /s/ Sepehr Sarshar

	Name: Sepehr Sarshar
	Its: Manager
	
	 Address:      2460 Oxford Avenue

                   
 Cardiff CA 92007

                   
 Attention: Sep Sarshar

 [SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 INVESTORS: 
  

			
	 PANORAMA CAPITAL, L.P.
  

By: Panorama Capital Management, LLC
 Its General
Partner

		
	By:	 	 /s/ Rodney A. Ferguson, Ph.D.

	Name: Rodney A. Ferguson, Ph.D.
	Its: Managing Director
	
	 Address:      1999 South Bascom Ave, Suite 700

                   
 Campbell, CA 95008

 [SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 INVESTORS: 
  

			
	DEERFIELD SPECIAL SITUATIONS FUND, L.P.
		
	By:	 	Deerfield Mgmt, L.P.
		 	General Partner

 
			
		
	        By:	 	J.E. Flynn Capital, LLC
		 	General Partner
		
	        By:	 	 /s/ David J. Clark

		 	Name: David J. Clark
		 	Title: Authorized Signatory

 
			
		
	Address:	 	  

		 	  

		 	  

  

			
	DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.
		
	By:	 	Deerfield Mgmt, L.P.
		 	General Partner

 
			
		
	        By:	 	J.E. Flynn Capital, LLC
		 	General Partner

 
					
			
		 	By:	 	 /s/ David J. Clark

		 	Name:	 	David J. Clark
		 	Title:	 	Authorized Signatory

 
			
		
	Address:	 	  

		 	  

		 	  

 [SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 INVESTORS: 
  

			
	DEERFIELD PRIVATE DESIGN FUND II, L.P.
		
	By:	 	Deerfield Mgmt, L.P.
		 	General Partner

 
			
		
	        By:	 	J.E. Flynn Capital, LLC
		 	General Partner

 
					
			
		 	By:	 	 /s/ David J. Clark

		 	Name:	 	David J. Clark
		 	Title:	 	Authorized Signatory

 
			
		
	Address:	 	  

		 	  

		 	  

  

			
	DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.
		
	By:	 	Deerfield Mgmt, L.P.
		 	General Partner

 
			
		
	        By:	 	J.E. Flynn Capital, LLC
		 	General Partner

 
					
			
		 	By:	 	 /s/ David J. Clark

		 	Name:	 	David J. Clark
		 	Title:	 	Authorized Signatory

 
			
		
	Address:	 	  

		 	  

		 	  

 [SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 INVESTORS: 
  

			
	BMV DIRECT LP
		
	By:	 	 /s/ Jonathan P. Klassen

	 Name: Jonathan P. Klassen
 Title:
Senior Vice President

 
			
		
	Address:	 	  

		 	  

		 	  

 [SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 EXHIBIT A 

SERIES A INVESTORS 

HOUMAN SARSHAR 

SEPEHR SARSHAR 

THE AFY NEVADA TRUST 

FARHAD YOUSEFZADEH 

SUSHIL NEEL ASIKAR 

ROHAN TAHILIANI AGGARWAL 

ASHA MADHU AGGARWAL 

SERIES B INVESTORS 
 THOMAS, MCNERNEY
& PARTNERS II, L.P. 
 TMP NOMINEE II, LLC 

TMP ASSOCIATES II, L.P. 

CMEA VENTURES VII, L.P. 

CMEA VENTURES VII (PARALLEL), L.P. 

COSTA VERDE CAPITAL LLC 

HOUMAN SARSHAR 

SEPEHR SARSHAR 

THE AFY NEVADA TRUST 

FARHAD YOUSEFZADEH 

SERIES C INVESTORS 
  

THOMAS, MCNERNEY & PARTNERS II, L.P. 

TMP NOMINEE II, LLC 

TMP ASSOCIATES II, L.P. 

CMEA VENTURES VII, L.P. 

CMEA VENTURES VII (PARALLEL), L.P. 

COSTA VERDE CAPITAL LLC 

COSTA VERDE CAPITAL II LLC 

HOUMAN SARSHAR 

SEPEHR SARSHAR 

THE AFY NEVADA TRUST 

FARHAD YOUSEFZADEH 

SERIES D INVESTORS 
 THOMAS, MCNERNEY
& PARTNERS II, L.P. 

 TMP NOMINEE II, LLC 

TMP ASSOCIATES II, L.P. 

CMEA VENTURES VII, L.P. 

CMEA VENTURES VII (PARALLEL), L.P. 

PANORAMA CAPITAL, L.P. 

BMV DIRECT LP 

HOUMAN SARSHAR 

SEPEHR SARSHAR 

THE AFY NEVADA TRUST 

FARHAD YOUSEFZADEH 

SERIES E INVESTORS 
 THOMAS, MCNERNEY
& PARTNERS II, L.P. 
 TMP NOMINEE II, LLC 
 TMP ASSOCIATES
II, L.P. 
 CMEA VENTURES VII, L.P. 
 CMEA VENTURES VII
(PARALLEL), L.P. 
 PANORAMA CAPITAL, L.P. 
 BMV DIRECT LP 

COSTA VERDE CAPITAL LLC 
 DEERFIELD SPECIAL SITUATIONS FUND, L.P.

 DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P. 

DEERFIELD PRIVATE DESIGN FUND II, L.P. 
 DEERFIELD PRIVATE DESIGN
INTERNATIONAL II, L.P.EX-10.1

 Exhibit 10.1 

INDEMNIFICATION AGREEMENT 

THIS INDEMNIFICATION AGREEMENT (this “Agreement”)
dated as of             , is made by and between AUSPEX PHARMACEUTICALS, INC., A DELAWARE
CORPORATION (THE “Company”), and              (“Indemnitee”). 

RECITALS 

A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents.
 
 B. The Company’s bylaws (the “Bylaws”) require that the Company
indemnify its directors, and empowers the Company to indemnify its officers, employees and agents, as authorized by the Delaware General Corporation Law, as amended (the “Code”), under which the Company is organized and such
Bylaws expressly provide that the indemnification provided therein is not exclusive and contemplates that the Company may enter into separate agreements with its directors, officers and other persons to set forth specific indemnification
provisions. 
 C. Indemnitee does not regard the protection currently provided by applicable law, the Company’s
governing documents and available insurance as adequate under the present circumstances, and the Company has determined that Indemnitee and other directors, officers, employees and agents of the Company may not be willing to serve or continue to
serve in such capacities without additional protection. 
 D. The Company desires and has requested Indemnitee to serve or
continue to serve as a director, officer, employee or agent of the Company, as the case may be, and has proffered this Agreement to Indemnitee as an additional inducement to serve in such capacity. 

E. Indemnitee is willing to serve, or to continue to serve, as a director, officer, employee or agent of the Company, as the case may
be, if Indemnitee is furnished the indemnity provided for herein by the Company. 
 AGREEMENT 

NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein,
the parties hereto, intending to be legally bound, hereby agree as follows: 
 1. Definitions. 

(a) Agent. For purposes of this Agreement, the term “agent” of the Company means
any person who: (i) is or was a director, officer, employee or other fiduciary of the Company or a subsidiary of the Company; or (ii) is or was serving at the request or for the convenience of, or
representing the interests of, the Company or a subsidiary of the Company, as a director, officer, employee or other fiduciary of a foreign or domestic corporation, partnership, joint venture, trust or other enterprise.  

  
 1. 

 (b) Expenses. For purposes of this Agreement, the term
“expenses” shall be broadly construed and shall include, without limitation, all direct and indirect costs of any type or nature whatsoever (including, without limitation, all attorneys’, witness, or other professional
fees and related disbursements, and other out-of-pocket costs of whatever nature), actually and reasonably incurred by Indemnitee in connection with the investigation, defense or appeal of a proceeding or establishing or enforcing a right to
indemnification under this Agreement, the Code or otherwise, and amounts paid in settlement by or on behalf of Indemnitee, but shall not include any judgments, fines or penalties actually levied against Indemnitee for such individual’s
violations of law. The term “expenses” shall also include reasonable compensation for time spent by Indemnitee for which he is not compensated by the Company or any subsidiary or third party (i) for any period during which Indemnitee
is not an agent, in the employment of, or providing services for compensation to, the Company or any subsidiary; and (ii) if the rate of compensation and estimated time involved is approved by the directors of the Company who are not parties to
any action with respect to which expenses are incurred, for Indemnitee while an agent of, employed by, or providing services for compensation to, the Company or any subsidiary. 

(c) Proceedings. For purposes of this Agreement, the term “proceeding” shall be
broadly construed and shall include, without limitation, any threatened, pending, or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or
completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative or investigative nature, and whether formal or informal in any case, in which Indemnitee was, is or will be involved as a
party or otherwise by reason of: (i) the fact that Indemnitee is or was a director or officer of the Company; (ii) the fact that any action taken by Indemnitee or of any action on Indemnitee’s part while acting as director, officer,
employee or agent of the Company; or (iii) the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or
other enterprise, and in any such case described above, whether or not serving in any such capacity at the time any liability or expense is incurred for which indemnification, reimbursement, or advancement of expenses may be provided under this
Agreement. 
 (d) Subsidiary. For purposes of this Agreement, the term
“subsidiary” means any corporation or limited liability company of which more than 50% of the outstanding voting securities or equity interests are owned, directly or indirectly, by the Company and one or more of its
subsidiaries, and any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, employee,
agent or fiduciary. 
 (e) Independent Counsel. For purposes of this Agreement, the term “independent
counsel” means a law firm, or a partner (or, if applicable, member) of such a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five (5) years has been, retained to represent:
(i) the Company or Indemnitee in any matter material to either such party, or (ii) any other party to the proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “independent
counsel” shall not include any person who, under the applicable standards of professional conduct then 

  
 2. 

 
prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. 

2. Agreement to Serve. Indemnitee will serve, or continue to serve, as a director, officer, employee or agent of the Company or any
subsidiary, as the case may be, faithfully and to the best of his or her ability, at the will of such corporation (or under separate agreement, if such agreement exists), in the capacity Indemnitee currently serves as an agent of such corporation or
in such other capacity as agreed to between the Company and Indemnitee, so long as Indemnitee is duly appointed or elected and qualified in accordance with the applicable provisions of the bylaws or other applicable charter documents of such
corporation, or until such time as Indemnitee tenders his or her resignation in writing; provided, however, that nothing contained in this Agreement is intended as an employment agreement between Indemnitee and the Company or any of its subsidiaries
or to create any right to continued employment of Indemnitee with the Company or any of its subsidiaries in any capacity. 
 The
Company acknowledges that it has entered into this Agreement and assumes the obligations imposed on it hereby, in addition to and separate from its obligations to Indemnitee under the Bylaws, to induce Indemnitee to serve, or continue to serve, as a
director, officer, employee or agent of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director, officer, employee or agent of the Company. 

3. Indemnification. 

(a) Indemnification in Third Party Proceedings. Subject to Section 10 below, the Company shall indemnify Indemnitee to the fullest
extent permitted by the Code, as the same may be amended from time to time (but, only to the extent that such amendment permits Indemnitee to broader indemnification rights than the Code permitted prior to adoption of such amendment), if Indemnitee
is a party to or threatened to be made a party to or otherwise involved in any proceeding, for any and all expenses, actually and reasonably incurred by Indemnitee in connection with the investigation, defense, settlement or appeal of such
proceeding. 
 (b) Indemnification in Derivative Actions and Direct Actions by the Company. Subject to Section 10 below,
the Company shall indemnify Indemnitee to the fullest extent permitted by the Code, as the same may be amended from time to time (but, only to the extent that such amendment permits Indemnitee to broader indemnification rights than the Code
permitted prior to adoption of such amendment), if Indemnitee is a party to or threatened to be made a party to or otherwise involved in any proceeding by or in the right of the Company to procure a judgment in its favor, against any and all
expenses actually and reasonably incurred by Indemnitee in connection with the investigation, defense, settlement, or appeal of such proceedings. 

(c) Indemnification of Related Parties. If (i) Indemnitee is or was affiliated with one or more venture capital funds that
has invested in the Company (an “Appointing Stockholder”), (ii) the Appointing Stockholder is, or is threatened to be made, a party to or a participant in any proceeding, then the Appointing Stockholder will be entitled
to indemnification hereunder for Expenses to the same extent as Indemnitee, but only to the extent 

  
 3. 

 
that Indemnitee is or would be entitled to indemnification hereunder in the same or any related action or proceeding, and provided that any such indemnification shall be subject to the same
limitations set forth herein with respect to Indemnitee. 
 4. Indemnification of Expenses of Successful Party. Notwithstanding any
other provision of this Agreement, to the extent that Indemnitee has been successful on the merits or otherwise in defense of any proceeding or in defense of any claim, issue or matter therein, including the dismissal of any action without
prejudice, the Company shall indemnify Indemnitee against all expenses actually and reasonably incurred in connection with the investigation, defense or appeal of such proceeding. 

5. Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some
or a portion of any expenses actually and reasonably incurred by Indemnitee in the investigation, defense, settlement or appeal of a proceeding, but is precluded by applicable law or the specific terms of this Agreement to indemnification for the
total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. 

6. Advancement of Expenses. To the extent not prohibited by law, the Company shall advance the expenses incurred by Indemnitee in
connection with any proceeding, and such advancement shall be made within twenty (20) days after the receipt by the Company of a statement or statements requesting such advances (which shall include invoices received by Indemnitee in connection
with such expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included
with the invoice) and upon request of the Company, an undertaking to repay the advancement of expenses if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that
Indemnitee is not entitled to be indemnified by the Company. Advances shall be unsecured, interest free and without regard to Indemnitee’s ability to repay the expenses. Advances shall include any and all expenses actually and reasonably
incurred by Indemnitee pursuing an action to enforce Indemnitee’s right to indemnification under this Agreement, or otherwise and this right of advancement, including expenses incurred preparing and forwarding statements to the Company to
support the advances claimed. Indemnitee acknowledges that the execution and delivery of this Agreement shall constitute an undertaking providing that Indemnitee shall, to the fullest extent required by law, repay the advance if and to the extent
that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. The right to advances under this Section shall continue until final
disposition of any proceeding, including any appeal therein. This Section 6 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 10(b). 

7. Notice and Other Indemnification Procedures. 

(a) Notification of Proceeding. Indemnitee will notify the Company in writing promptly upon being served with any summons, citation,
subpoena, complaint, indictment, information or other document relating to any proceeding or matter which may be subject to indemnification or advancement of expenses covered hereunder. The failure of

  
 4. 

 
Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise. 

(b) Request for Indemnification and Indemnification Payments. Indemnitee shall notify the Company promptly in writing upon receiving
notice of any demand, judgment or other requirement for payment that Indemnitee reasonably believes to be subject to indemnification under the terms of this Agreement, and shall request payment thereof by the Company. Indemnification payments
requested by Indemnitee under Section 3 hereof shall be made by the Company no later than sixty (60) days after receipt of the written request of Indemnitee. Claims for advancement of expenses shall be made under the provisions of
Section 6 herein. 
 (c) Application for Enforcement. In the event the Company fails to make timely payments as set forth
in Sections 6 or 7(b) above, Indemnitee shall have the right to apply to any court of competent jurisdiction for the purpose of enforcing Indemnitee’s right to indemnification or advancement of expenses pursuant to this Agreement. In such an
enforcement hearing or proceeding, the burden of proof shall be on the Company to prove that indemnification or advancement of expenses to Indemnitee is not required under this Agreement or permitted by applicable law. Any determination by the
Company (including its Board of Directors, stockholders or independent counsel) that Indemnitee is not entitled to indemnification hereunder, shall not be a defense by the Company to the action nor create any presumption that Indemnitee is not
entitled to indemnification or advancement of expenses hereunder. 
 (d) Indemnification of Certain Expenses. The Company
shall indemnify Indemnitee against all expenses incurred in connection with any hearing or proceeding under this Section 7 unless the Company prevails in such hearing or proceeding on the merits in all material respects. 

8. Assumption of Defense. In the event the Company shall be requested by Indemnitee to pay the expenses of any proceeding, the Company,
if appropriate, shall be entitled to assume the defense of such proceeding, or to participate to the extent permissible in such proceeding, with counsel reasonably acceptable to Indemnitee. Upon assumption of the defense by the Company and the
retention of such counsel by the Company, the Company shall not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same proceeding, provided that Indemnitee shall have the
right to employ separate counsel in such proceeding at Indemnitee’s sole cost and expense. Notwithstanding the foregoing, if Indemnitee’s counsel delivers a written notice to the Company stating that such counsel has reasonably concluded
that there may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense or the Company shall not, in fact, have employed counsel or otherwise actively pursued the defense of such proceeding within a reasonable
time, then in any such event the fees and expenses of Indemnitee’s counsel to defend such proceeding shall be subject to the indemnification and advancement of expenses provisions of this Agreement. 

9. Insurance. To the extent that the Company maintains an insurance policy or policies providing liability
insurance for directors, officers, employees, or agents of the Company or of any subsidiary (“D&O Insurance”), Indemnitee shall be covered by such policy  

  
 5. 

 
or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at
the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has D&O Insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures
set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such
policies. The Company hereby acknowledges that Indemnitee may have certain rights to indemnification, advancement of expenses and/or insurance provided by certain of his or her affiliates (collectively, the “Other
Indemnitors”). The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Other Indemnitors to advance expenses or to provide indemnification
for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all expenses, judgments,
penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement, the Certificate of Incorporation or Bylaws of the Company, or any D&O Insurance (or any other agreement between the
Company and Indemnitee), without regard to any rights Indemnitee may have against the Other Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Other Indemnitors from any and all claims against the Other
Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Other Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee
has sought indemnification from the Company shall affect the foregoing and the Other Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee
against the Company. The Company and Indemnitee agree that the Other Indemnitors are express third party beneficiaries of the terms of this Section 9. 

10. Exceptions. 

(a) Certain Matters. Any provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of
this Agreement to indemnify Indemnitee on account of any proceeding with respect to (i) remuneration paid to Indemnitee if it is determined by final judgment or other final adjudication that such remuneration was in violation of law (and, in
this respect, both the Company and Indemnitee have been advised that the Securities and Exchange Commission believes that indemnification for liabilities arising under the federal securities laws is against public policy and is, therefore,
unenforceable and that claims for indemnification should be submitted to appropriate courts for adjudication, as indicated in Section 10(d) below); (ii) a final judgment rendered against Indemnitee for an accounting, disgorgement or
repayment of profits made from the purchase or sale by Indemnitee of securities of the Company against Indemnitee pursuant to the provisions of Section 16(b) of the Securities Exchange Act of 1934, as amended, or other provisions of any
federal, state or local statute or rules and regulations thereunder; (iii) a final judgment or other final adjudication that Indemnitee’s conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful
misconduct (but only to the extent of such specific determination); or (iv) on account of conduct that is established by a final judgment as constituting a breach of Indemnitee’s duty of loyalty to the Company or resulting in any personal
profit or advantage to 

  
 6. 

 
which Indemnitee is not legally entitled. For purposes of the foregoing sentence, a final judgment or other adjudication may be reached in either the underlying proceeding or action in connection
with which indemnification is sought or a separate proceeding or action to establish rights and liabilities under this Agreement. 
 (b)
Claims Initiated by Indemnitee. Any provision herein to the contrary notwithstanding, the Company shall not be obligated to indemnify or advance expenses to Indemnitee with respect to proceedings or claims initiated or brought by Indemnitee
against the Company or its directors, officers, employees or other agents and not by way of defense, except (i) with respect to proceedings brought to establish or enforce a right to indemnification under this Agreement or under any other
agreement, provision in the Bylaws or Certificate of Incorporation or applicable law, or (ii) with respect to any other proceeding initiated by Indemnitee that is either approved by the Board of Directors or Indemnitee’s participation is
required by applicable law. However, indemnification or advancement of expenses may be provided by the Company in specific cases if the Board of Directors determines it to be appropriate. 

(c) Unauthorized Settlements. Any provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the
terms of this Agreement to indemnify Indemnitee under this Agreement for any amounts paid in settlement of a proceeding effected without the Company’s written consent. Neither the Company nor Indemnitee shall unreasonably withhold consent to
any proposed settlement; provided, however, that the Company may in any event decline to consent to (or to otherwise admit or agree to any liability for indemnification hereunder in respect of) any proposed settlement if the Company is also a party
in such proceeding and determines in good faith that such settlement is not in the best interests of the Company and its stockholders. 

(d) Securities Act Liabilities. Any provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to
the terms of this Agreement to indemnify Indemnitee or otherwise act in violation of any undertaking appearing in and required by the rules and regulations promulgated under the Securities Act of 1933, as amended (the “Act”), or in any
registration statement filed with the SEC under the Act. Indemnitee acknowledges that paragraph (h) of Item 512 of Regulation S-K currently generally requires the Company to undertake in connection with any registration statement filed
under the Act to submit the issue of the enforceability of Indemnitee’s rights under this Agreement in connection with any liability under the Act on public policy grounds to a court of appropriate jurisdiction and to be governed by any final
adjudication of such issue. Indemnitee specifically agrees that any such undertaking shall supersede the provisions of this Agreement and to be bound by any such undertaking. 

11. Nonexclusivity and Survival of Rights. The provisions for indemnification and advancement of expenses set forth in this Agreement
shall not be deemed exclusive of any other rights which Indemnitee may at any time be entitled under any provision of applicable law, the Company’s Certificate of Incorporation, Bylaws or other agreements, both as to action in Indemnitee’s
official capacity and Indemnitee’s action as an agent of the Company, in any court in which a proceeding is brought, and Indemnitee’s rights hereunder shall continue after Indemnitee has ceased acting as an agent of the Company and shall
inure to the benefit of the 

  
 7. 

 
heirs, executors, administrators and assigns of Indemnitee. The obligations and duties of the Company to Indemnitee under this Agreement shall be binding on the Company and its successors and
assigns until terminated in accordance with its terms. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company,
expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. 

No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this
Agreement in respect of any action taken or omitted by such Indemnitee in his or her corporate status prior to such amendment, alteration or repeal. To the extent that a change in the Code, whether by statute or judicial decision, permits greater
indemnification or advancement of expenses than would be afforded currently under the Company’s Certificate of Incorporation, Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the
greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given
hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, by Indemnitee shall not prevent the concurrent assertion or employment of any other right or remedy
by Indemnitee. 
 12. Term. This Agreement shall continue until and terminate upon the later of: (a) five (5) years after
the date that Indemnitee shall have ceased to serve as a director or and/or officer, employee or agent of the Company; or (b) one (1) year after the final termination of any proceeding, including any appeal then pending, in respect to
which Indemnitee was granted rights of indemnification or advancement of expenses hereunder.  
 No legal action shall be brought and
no cause of action shall be asserted by or in the right of the Company against an Indemnitee or an Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the expiration of five (5) years from the date of
accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such five-year period; provided, however, that if any shorter
period of limitations is otherwise applicable to such cause of action, such shorter period shall govern. 
 13. Subrogation. In the
event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who, at the request and expense of the Company, shall execute all papers required and shall do
everything that may be reasonably necessary to secure such rights, including the execution of such documents necessary to enable the Company effectively to bring suit to enforce such rights. 

14. Interpretation of Agreement. It is understood that the parties hereto intend this Agreement to be interpreted and enforced so as to
provide indemnification to Indemnitee to the fullest extent now or hereafter permitted by law. 

  
 8. 

 15. Severability. If any provision of this Agreement shall be held to be invalid, illegal
or unenforceable for any reason whatsoever, (a) the validity, legality and enforceability of the remaining provisions of the Agreement (including without limitation, all portions of any paragraphs of this Agreement containing any such provision
held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Agreement (including,
without limitation, all portions of any paragraph of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the
intent manifested by the provision held invalid, illegal or unenforceable and to give effect to Section 14 hereof. 
 16.
Amendment and Waiver. No supplement, modification, amendment, or cancellation of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall
constitute a waiver of any other provision hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.  

17. Notice. Except as otherwise provided herein, any notice or demand which, by the provisions hereof, is required or which may be
given to or served upon the parties hereto shall be in writing and, if by telegram, telecopy or telex, shall be deemed to have been validly served, given or delivered when sent, if by overnight delivery, courier or personal delivery, shall be deemed
to have been validly served, given or delivered upon actual delivery and, if mailed, shall be deemed to have been validly served, given or delivered three (3) business days after deposit in the United States mail, as registered or certified
mail, with proper postage prepaid and addressed to the party or parties to be notified at the addresses set forth on the signature page of this Agreement (or such other address(es) as a party may designate for itself by like notice). If to the
Company, notices and demands shall be delivered to the attention of the Secretary of the Company. 
 18. Governing Law. This
Agreement shall be governed exclusively by and construed according to the laws of the State of Delaware, as applied to contracts between Delaware residents entered into and to be performed entirely within Delaware. 

19. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an
original but all of which together shall constitute but one and the same Agreement. Only one such counterpart need be produced to evidence the existence of this Agreement. 

20. Headings. The headings of the sections of this Agreement are inserted for convenience only and shall not be deemed to constitute
part of this Agreement or to affect the construction hereof. 
 21. Entire Agreement. This Agreement constitutes the entire
agreement between the parties with respect to the subject matter hereof and amends, restates and supersedes all prior agreements, understandings and negotiations, written and oral, between the parties with respect to the subject matter of this
Agreement, including but not limited to any Indemnity Agreement previously entered into between the undersigned and the Company; provided, however, that this 

  
 9. 

 
Agreement is a supplement to and in furtherance of the Company’s Certificate of Incorporation, Bylaws, the Code and any other applicable law, and shall not be deemed a substitute therefor,
and does not diminish or abrogate any rights of Indemnitee thereunder. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 IN WITNESS WHEREOF, the
parties hereto have entered into this Agreement effective as of the date first above written. 
  

			
	“COMPANY”
	
	Auspex Pharmaceuticals, Inc.
		
	By:	 	 

 
			
		
	Name:	 	 

 
			
		
	Title:	 	 

  

	
	 INDEMNITEE
  

	 Signature of Indemnitee

 

	
	
	 Print or Type Name of Indemnitee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]